Jun 2026 (Q2 FY26) — Aug 13, 2026
Karyopharm Q2 FY26 — Myelofibrosis sNDA Submission on Track, Financial Headwinds Addressed
Read the full callKaryopharm (KPTI) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Karyopharm earnings: last reported Thu, 13 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 33.4 | −11.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -67.4 | −3.1 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -67.0 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$0.35 −10.26% · −$0.04
Performance −94.1% 1Y
1Y: $5.93 on 17 Oct 2025 → $0.35. High $10.67 (8 Jul 2026), low $0.32 (14 Oct 2026).
- Previous close
- $0.39
- 52-week range
- $0.32 – $10.67
- One year
- −94.59%
Overview
- Symbol
- KPTI
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Karyopharm earnings calls (KPTI)
Financials
What the filings say
Net profit, year on year: −80% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 39 | 31 | 30 | 38 | 44 | 34 | 35 | 33 |
| Operating profit | -26 | -31 | -33 | -24 | -15 | -18 | -27 | -23 |
| Operating margin | −67.8% | −102.4% | −110.8% | −64.3% | −34.6% | −52.4% | −76.3% | −67.4% |
| Other income | -6 | 0 | 10 | -13 | -18 | -84 | 4 | -44 |
| Interest | 11 | 11 | 11 | 11 | 11 | 13 | 13 | 13 |
| Profit before tax | -32 | -31 | -23 | -37 | -33 | -102 | -22 | -67 |
| Tax rate | −0.1% | 0.3% | −0.1% | −0.1% | −0.1% | 0.1% | 0.0% | 0.0% |
| Net profit | -32 | -31 | -23 | -37 | -33 | -102 | -22 | -67 |
| EPS ($ per share) | -3.85 | — | -2.77 | -4.32 | -3.82 | — | -1.02 | -2.32 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -674 | -873 | -1,070 | -1,179 | -1,344 | -1,487 | -1,563 | -1,759 |
| Total liabilities | 158 | 245 | 263 | 385 | 375 | 377 | 350 | 401 |
| Fixed assets | 4 | 3 | 2 | 2 | 1 | 1 | 0 | 0 |
| Total assets | 341 | 295 | 313 | 305 | 358 | 240 | 164 | 108 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -159 | -191 | -160 | -107 | -150 | -93 | -127 | -75 |
| Cash from investing | -108 | 78 | -54 | 142 | -104 | 8 | 95 | 43 |
| Cash from financing | 316 | 124 | 172 | 74 | 194 | 1 | 42 | 30 |
| Net cash flow | 49 | 12 | -42 | 108 | -61 | -84 | 10 | -2 |
| Capital expenditure | -2 | -0 | -0 | -0 | -0 | 0 | -0 | 0 |
| Free cash flow | -161 | -191 | -160 | -107 | -150 | -93 | -128 | -75 |
Insider filings
39 filings between Jan 21, 2026 and Oct 1, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$349.8K
20 sales by 7 insiders
Compensation
not trading decisions- 19
- Award — granted as compensation
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Paulson Richard A. | — | $137.2K | May 14, 2026 |
| Poulton Stuart | — | $56.4K | Jul 28, 2026 |
| Rangwala Reshma | — | $55.6K | May 14, 2026 |
| Cheng Sohanya Roshan | — | $46.4K | May 14, 2026 |
| Mano Michael | — | $35.7K | May 14, 2026 |
| Macomber Lori | — | $10.2K | Feb 3, 2026 |
| Abate Kristin | — | $8.2K | Oct 1, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 1, 2026 | Abate Kristin Chief Accounting Officer | Sale | 378 | $450 |
| Sep 1, 2026 | Abate Kristin Chief Accounting Officer | Sale | 19 | $38 |
| Jul 28, 2026 | Poulton Stuart EVP, Chief Development Officer | Sale | 189 | $1.3K |
| May 21, 2026 | Su Zhen Director | Award | 15,508 | $0 |
| May 21, 2026 | Greene Barry E Director | Award | 15,508 | $0 |
| May 21, 2026 | Schor Chen Director | Award | 15,508 | $0 |
| May 21, 2026 | Oliger Christy J. Director | Award | 15,508 | $0 |
| May 21, 2026 | BOHLIN GAREN G Director | Award | 15,508 | $0 |
| May 21, 2026 | PAKIANATHAN DEEPIKA Director | Award | 15,508 | $0 |
| May 14, 2026 | Abate Kristin Chief Accounting Officer | Sale | 53 | $504 |
| May 14, 2026 | Rangwala Reshma EVP & Chief Medical Officer | Sale | 408 | $3.9K |
| May 14, 2026 | Paulson Richard A. President and CEO | Sale | 2,203 | $20.9K |
| May 14, 2026 | Poulton Stuart EVP, Chief Development Officer | Sale | 403 | $3.8K |
| May 14, 2026 | Mano Michael EVP, CLO&Secretary | Sale | 266 | $2.5K |
| May 14, 2026 | Cheng Sohanya Roshan EVP & Chief Commercial Officer | Sale | 324 | $3.1K |
| May 13, 2026 | Rangwala Reshma EVP & Chief Medical Officer | Award | 947 | $0 |
| May 13, 2026 | Abate Kristin Chief Accounting Officer | Award | 121 | $0 |
| May 13, 2026 | Cheng Sohanya Roshan EVP & Chief Commercial Officer | Award | 947 | $0 |
| May 13, 2026 | Paulson Richard A. President and CEO | Award | 4,920 | $0 |
| May 13, 2026 | Poulton Stuart EVP, Chief Development Officer | Award | 896 | $0 |
| May 13, 2026 | Mano Michael EVP, CLO&Secretary | Award | 700 | $0 |
| Apr 21, 2026 | Rangwala Reshma EVP & Chief Medical Officer | Sale | 449 | $4.0K |
| Mar 2, 2026 | Cheng Sohanya Roshan EVP & Chief Commercial Officer | Sale | 4,604 | $43.3K |
| Mar 2, 2026 | Paulson Richard A. President and CEO | Sale | 12,361 | $116.3K |
| Mar 2, 2026 | Rangwala Reshma EVP & Chief Medical Officer | Sale | 5,066 | $47.7K |
| Mar 2, 2026 | Mano Michael EVP, CLO&Secretary | Sale | 3,526 | $33.2K |
| Mar 2, 2026 | Poulton Stuart EVP, Chief Development Officer | Sale | 5,101 | $48.0K |
| Mar 2, 2026 | Abate Kristin Chief Accounting Officer | Sale | 559 | $5.3K |
| Feb 17, 2026 | Poulton Stuart EVP, Chief Development Officer | Sale | 378 | $3.3K |
| Feb 5, 2026 | Paulson Richard A. President and CEO | Award | 81,060 | $0 |
| Feb 3, 2026 | Macomber Lori EVP, CFO & Treasurer | Sale | 1,626 | $10.2K |
| Jan 31, 2026 | Macomber Lori EVP, CFO & Treasurer | Award | 32,415 | $0 |
| Jan 31, 2026 | Rangwala Reshma EVP & Chief Medical Officer | Award | 32,415 | $0 |
| Jan 31, 2026 | Cheng Sohanya Roshan EVP & Chief Commercial Officer | Award | 32,415 | $0 |
| Jan 31, 2026 | Mano Michael EVP, CLO&Secretary | Award | 32,415 | $0 |
| Jan 31, 2026 | Poulton Stuart EVP, Chief Development Officer | Award | 32,415 | $0 |
| Jan 28, 2026 | Abate Kristin Chief Accounting Officer | Sale | 50 | $352 |
| Jan 27, 2026 | Abate Kristin Chief Accounting Officer | Award | 92 | $0 |
| Jan 21, 2026 | Abate Kristin Chief Accounting Officer | Sale | 265 | $1.6K |
| Oct 15, 2025 | Abate Kristin Chief Accounting Officer | Award | 12,799 | $0 |
| Oct 15, 2025 | Mano Michael SVP, General Counsel&Secretary | Award | 43,650 | $0 |
| Oct 15, 2025 | Poulton Stuart EVP, Chief Development Officer | Award | 39,682 | $0 |
| Oct 15, 2025 | Paulson Richard A. President and CEO | Award | 114,285 | $0 |
| Oct 15, 2025 | Macomber Lori EVP, CFO & Treasurer | Award | 43,650 | $0 |
| Oct 15, 2025 | Cheng Sohanya Roshan EVP & Chief Commercial Officer | Award | 43,650 | $0 |
| Oct 1, 2025 | Abate Kristin Chief Accounting Officer | Sale | 362 | $2.3K |
| Sep 15, 2025 | Abate Kristin Chief Accounting Officer | Sale | 23 | $148 |
| Sep 15, 2025 | Cheng Sohanya Roshan EVP & Chief Commercial Officer | Sale | 325 | $2.1K |
| Sep 15, 2025 | Rangwala Reshma EVP & Chief Medical Officer | Sale | 408 | $2.6K |
| Sep 15, 2025 | Poulton Stuart EVP, Chief Development Officer | Sale | 401 | $2.6K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Karyopharm Therapeutics Inc.
Free account. Everything above stays public.
Write why you follow Karyopharm Therapeutics Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading